Trial Information
A Phase 2, Open-label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
Inclusion Criteria:
- Recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen
containing a platinum agent
- Recovery from all acute side effects of prior therapies (with the exception of hair
loss)
- Adequate bone marrow, liver, and kidney function
Exclusion Criteria:
- More than 2 prior chemotherapy regimens for treatment of advanced or metastatic
non-small cell lung cancer. (Treatment given in conjunction with surgery will not be
included in the maximum of 2 prior regimens)
- Radiation therapy, chemotherapy or any other anticancer therapy within 28 days of
beginning study
- Symptomatic brain metastases
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Medical Monitor, MD
Investigator Role:
Study Director
Investigator Affiliation:
Wyeth is now a wholly owned subsidiary of Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
3128K1-201
NCT ID:
NCT00063219
Start Date:
Completion Date:
February 2005
Related Keywords:
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Non-Small-Cell Lung Carcinoma
- Lung Cancer
- Cancer of Lung
- Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|
Alexandria, Minnesota 56308 |
|
Fountain Valley, California 92708 |
|
Columbia, Missouri 65203 |
|
Albany, New York 12208 |
|
Cleveland, Ohio 44195 |
|
Philadelphia, Pennsylvania 19104 |
|
Nashville, Tennessee 37203-1632 |
|
Louisville, Kentucky 40207 |
|
Baltimore, Maryland 21287 |
|
Boston, Massachusetts |
|
Charlotte, North Carolina |
|
Charleston, South Carolina |